ArticleJournal of enzyme inhibition and medicinal chemistry2023
Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from
Open access · goldAbstract read
In one paragraph
Article in Journal of enzyme inhibition and medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 57 citations in OpenAlex.
- Design, synthesis and antiproliferative activity of oxadiazole derivatives as potent glycogen synthase kinase-3/histone deacetylase 6 dual inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Design, synthesis, and biological evaluation of aminopyrazine-based ATR/HDACs dual inhibitors.Molecular diversity · 2026Article
- Riding the Wave of Progress: Examining the Current Landscape and Future Potential of MicroRNAs in Cancer Gene Therapy.Current gene therapy · 2026Review
- Targeted Protein Degradation in Lung Cancer: The Emerging Role of PROTAC Technology and E3 Ligases.Current medicinal chemistry · 2026Review
- Structure-based design of anticancer drugs based on β-elemene: Research foundations and development potential.Journal of pharmaceutical analysis · 2025Review
- Optimizing kinase and PARP inhibitor combinations through machine learning and in silico approaches for targeted brain cancer therapy.Molecular diversity · 2025Article
- Thiazole derivatives in cancer therapy: mechanistic insights, bioactivity, and future perspective.Future medicinal chemistry · 2025Review
- ADME analysis, metabolic prediction, and molecular docking of lipoic acid with SARS-CoV-2 Omicron spike protein.Scientific reports · 2025Article
- Facile indazole-endowed thiadiazole hybrid derivatives as antibacterial, anti-diabetic and thymidine phosphorylase inhibitors: An insight to experimental, in-vitro biological potential and computational approaches.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Article
- Histone Deacetylase 6 (HDAC6) in Ciliopathies: Emerging Insights and Therapeutic Implications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Molecular docking of Cu(II) and Zn(II) complexes for tyrosinase inhibition and drug loading on boron nitride nanotube scaffolds using Monte Carlo simulations.Journal of molecular modeling · 2025Article
- Comprehensive assessment of 3-benzyloxyflavones as β-glucosidase inhibitors:RSC advances · 2025Article
- Comparison of Two Synthesis Methods for 3D PLA-Ibuprofen Nanofibrillar Scaffolds.Pharmaceutics · 2025Article
- Article
- Designing novel cabozantinib analogues as p-glycoprotein inhibitors to target cancer cell resistance using molecular docking study, ADMET screening, bioisosteric approach, and molecular dynamics simulations.Frontiers in chemistry · 2025Article
- Therapeutic potential ofFrontiers in chemistry · 2025Article
- Design, synthesis,Frontiers in chemistry · 2025Article
- Design and synthesis of triazolopyridine derivatives as potent JAK/HDAC dual inhibitors with broad-spectrum antiproliferative activity.Journal of enzyme inhibition and medicinal chemistry · 2024Article
- The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The role of artificial intelligence in drug screening, drug design, and clinical trials.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Yuan GaoInstitute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jilong DuanKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, China.
Xiawen DangKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, China.
Yinghui YuanKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, China.
Yu WangResearch and Development, Dalian HolleyKingkong Pharmaceutical Co. Ltd, Liaoning, China.
Xingrui HeKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, China.
Renren BaiKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, China.
Xiang-Yang YeKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, China.
Tian XieInstitute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Hangzhou Normal University · CNState Administration of Traditional Chinese Medicine of the People's Republic of China · CNDaewoong Pharmaceutical (South Korea) · KRShanghai University of Traditional Chinese Medicine · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic AgentsHistone Deacetylase InhibitorsAnimalsCell Line, TumorCell ProliferationDrug DesignDrug Screening Assays, AntitumorHistone Deacetylase 1Histone DeacetylasesMiceSesquiterpenesStructure-Activity RelationshipAntineoplastic Agentsbeta-elemeneHistone Deacetylase 1Histone Deacetylase InhibitorsHistone DeacetylasesSesquiterpenesHistone deacetylase inhibitorHybrid drugsLymphomaβ-Elemene
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.